Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Efficacy of Polymer-Free Drug-Eluting Stents.
Chiarito M, Sardella G, Colombo A, Briguori C, Testa L, Bedogni F, Fabbiocchi F, Paggi A, Palloshi A, Tamburino C, Margonato A, Pivato CA, Baber U, Calcagno S, Giordano A, Godino C, Stefanini GG. Chiarito M, et al. Among authors: stefanini gg. Circ Cardiovasc Interv. 2019 Feb;12(2):e007311. doi: 10.1161/CIRCINTERVENTIONS.118.007311. Circ Cardiovasc Interv. 2019. PMID: 30767663
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.
Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jüni P. Stefanini GG, et al. Lancet. 2011 Dec 3;378(9807):1940-8. doi: 10.1016/S0140-6736(11)61672-3. Epub 2011 Nov 8. Lancet. 2011. PMID: 22075451 Free article. Clinical Trial.
Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, Serruys PW, Windecker S. Räber L, et al. Among authors: stefanini gg. Circulation. 2012 Mar 6;125(9):1110-21. doi: 10.1161/CIRCULATIONAHA.111.058560. Epub 2012 Feb 1. Circulation. 2012. PMID: 22302840
Long-term comparison of everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes.
Kalesan B, Stefanini GG, Räber L, Schmutz M, Baumgartner S, Hitz S, Baldinger SH, Pilgrim T, Moschovitis A, Wenaweser P, Büllesfeld L, Khattab AA, Meier B, Jüni P, Windecker S. Kalesan B, et al. Among authors: stefanini gg. JACC Cardiovasc Interv. 2012 Feb;5(2):145-54. doi: 10.1016/j.jcin.2011.11.005. JACC Cardiovasc Interv. 2012. PMID: 22361598 Free article.
Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Jüni P, Schömig A, Windecker S, Kastrati A. Stefanini GG, et al. Eur Heart J. 2012 May;33(10):1214-22. doi: 10.1093/eurheartj/ehs086. Epub 2012 Mar 24. Eur Heart J. 2012. PMID: 22447805 Free article.
The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents.
Pilgrim T, Vetterli F, Kalesan B, Stefanini GG, Räber L, Stortecky S, Gloekler S, Binder RK, Wenaweser P, Moschovitis A, Khattab AA, Buellesfeld L, Zwahlen M, Meier B, Jüni P, Windecker S. Pilgrim T, et al. Among authors: stefanini gg. Circ Cardiovasc Interv. 2012 Apr;5(2):202-10. doi: 10.1161/CIRCINTERVENTIONS.111.965749. Epub 2012 Mar 27. Circ Cardiovasc Interv. 2012. PMID: 22456025
310 results